How many clinical trials are running for adagrasib?

ClinicalTrials.gov currently lists 15 phase 2–4 adagrasib trials: 11 phase 2, 4 phase 3, and 0 phase 4. 5 are actively recruiting.

Where does this data come from?

All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.

Can I compare adagrasib against other drugs?

Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.

KRAS inhibitors · Live ClinicalTrials.gov data

Adagrasib (Krazati) clinical trial pipeline

ClinicalTrials.gov lists 15 phase 2–4 trials for adagrasib, 5 of them actively recruiting. The next phase 3 primary completion among them is expected Sept 2029. Refreshed daily — add up to four competitors to compare pipelines side by side.

Phase 2–4 trials

Phase 3 trials

Actively recruiting

Sept 2029

Next phase 3 primary completion

3,704

Participants across trials

Mirati Therapeutics Inc.

Lead sponsor by trial count

adagrasib (15)15 active2019–2031

Hide completed

adagrasib

Key

Actual date

Anticipated

Forecast to primary completion

RecruitingActive, not recruitingNot yet recruitingWithdrawnUnknown status

'19

'20

'21

'22

'23

'24

'25

'26

'27

'28

'29

'30

'31

adagrasib

Genetic Testing in Guiding Treatment for Patients With Brain MetastasesP2

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7P2

KRYSTAL-12P3

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)P3

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationP2

Neo-KanP2

ADEPPTP2

A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and PanitumumabP2

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)P2

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain MetastasesP2

Krascendo 1P3

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)P3

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialP2

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesP2

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung CancerP2

Upcoming readouts

9 ahead · adagrasib

Select a trial to load its full ClinicalTrials.gov record.

Key adagrasib trials

Top 12 of the 15 registered phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.

Trial	Title	Phase	Status	Primary completion
NCT06875310	A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in …	Phase 3	Recruiting	Sept 2029
NCT04685135	KRYSTAL-12 — Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KR…	Phase 3	Active, not recruiting	Dec 2023
NCT04793958	Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS …	Phase 3	Active, not recruiting	Jan 2026
NCT06497556	Krascendo 1 — A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Pre…	Phase 3	Active, not recruiting	May 2026
NCT06248606	Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases	Phase 2	Recruiting	Feb 2027
NCT07415031	A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies	Phase 2	Recruiting	Feb 2028
NCT07288034	Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-lin…	Phase 2	Recruiting	Oct 2028
NCT04613596	Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib …	Phase 2	Recruiting	Oct 2028
NCT05673187	ADEPPT — Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status	Phase 2	Active, not recruiting	Jul 2025
NCT05853575	Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)	Phase 2	Active, not recruiting	Jul 2026
NCT05609578	Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation	Phase 2	Active, not recruiting	Sept 2026
NCT03994796	Genetic Testing in Guiding Treatment for Patients With Brain Metastases	Phase 2	Active, not recruiting	Oct 2026

Compare adagrasib vs sotorasib Compare adagrasib vs divarasib

FAQ

How many clinical trials are running for adagrasib?: ClinicalTrials.gov currently lists 15 phase 2–4 adagrasib trials: 11 phase 2, 4 phase 3, and 0 phase 4. 5 are actively recruiting.
Where does this data come from?: All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
Can I compare adagrasib against other drugs?: Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.

Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.

Upcoming readouts

Key adagrasib trials

Related drug pipelines

FAQ

Be the first to access ComplyRx